Panelists discuss how combination trials like VIALE-A and VIALE-C have demonstrated venetoclax’s survival benefits when added to hypomethylating agents, opening doors for numerous combination studies ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...

Discover the challenges of acute myeloid leukaemia linked to inflammatory cell death and the quest for effective therapies.

In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how ...

The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

The US Food and Drug Administration (FDA) has approved an oral form of azacitidine (Onureg) for use as maintenance therapy for patients with acute myeloid leukemia (AML) who have achieved a first ...

Acute myeloid leukemia (AML) is a rare and aggressive hematologic malignancy. AML progresses rapidly and is indicated by an excess of immature white blood cells. It is caused by high mutational burden ...

Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a type of cancer that starts in your bone marrow (the soft, spongy tissue inside the bones that makes blood cells). AML is ...